Predictive value of gross classification of hepatocellular carcinoma on recurrence and survival after hepatectomy

被引:115
作者
Hui, AM
Takayama, T
Sano, K
Kubota, K
Akahane, M
Ohtomo, K
Makuuchi, M
机构
[1] Univ Tokyo, Grad Sch Med, Dept Surg, Div Hepato Biliary Pancreat Surg,Bunkyo Ku, Tokyo 1130033, Japan
[2] Univ Tokyo, Grad Sch Med, Dept Radiol, Bunkyo Ku, Tokyo 1130033, Japan
关键词
gross classification; hepatocellular carcinoma; recurrence; survival;
D O I
10.1016/S0168-8278(00)80131-2
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aim: A new gross classification of hepatocellular carcinoma in which Eggel's nodular type is subclassified into type 1 (single nodular type), type 2 (single nodular type with extranodular growth), and type 3 (contiguous multinodular type) has been widely used in Japan. The aim of the study was to determine whether this classification is correlated with patient outcome. Methods: Sixty-five resected hepatocellular carcinoma nodules (less than or equal to5 cm) were classified using this new classification. Results: The 65 tumors were classified into 30 type 1 (46%), 20 type 2 (31%), and 15 type 3 (23%) hepatocellular carcinomas. The rate of microscopic vascular invasion significantly increased from type 1 to type 2, and to type 3 tumors (p=0.03), Kaplan-Meier estimates showed that type 1 was significantly associated with lower recurrence rate (type 1 vs type 2, p=0.01; type 1 vs. type 3, p=0.004; log-rank test), and higher disease-specific survival (type 1 vs. type 2, p=0.02; type 1 vs. type 3, p=0.002), Cox's proportional-hazards model demonstrated that type 1 was an independent factor for low risk of recurrence (p=0.002) and low risk of disease-specific death (p=0.02), Conclusion: The gross classification of hepatocellular carcinoma is of clinical value in predicting patient outcome.
引用
收藏
页码:975 / 979
页数:5
相关论文
共 31 条
[1]   INTRAHEPATIC RECURRENCE AFTER RESECTION OF HEPATOCELLULAR-CARCINOMA COMPLICATING CIRRHOSIS [J].
BELGHITI, J ;
PANIS, Y ;
FARGES, O ;
BENHAMOU, JP ;
FEKETE, F .
ANNALS OF SURGERY, 1991, 214 (02) :114-117
[2]  
Eggel H, 1901, BEITR PATHOL ANAT AL, V30, P506
[3]  
HIROHASHI S, 1992, PRIMARY LIVER CANC J, P25
[4]   Inactivation of p16(INK4) in hepatocellular carcinoma [J].
Hui, AM ;
Sakamoto, M ;
Kanai, Y ;
Ino, Y ;
Gotoh, M ;
Yokota, J ;
Hirohashi, S .
HEPATOLOGY, 1996, 24 (03) :575-579
[5]   Reduced p21(WAF1/CIP1) expression and p53 mutation in hepatocellular carcinomas [J].
Hui, AM ;
Kanai, Y ;
Sakamoto, M ;
Tsuda, H ;
Hirohashi, S .
HEPATOLOGY, 1997, 25 (03) :575-579
[6]   RISK-FACTORS LINKED TO TUMOR RECURRENCE OF HUMAN HEPATOCELLULAR-CARCINOMA AFTER HEPATIC RESECTION [J].
JWO, SC ;
CHIU, JH ;
CHAU, GY ;
LOONG, CC ;
LUI, WY .
HEPATOLOGY, 1992, 16 (06) :1367-1371
[7]  
KAKAZU T, 1993, HEPATO-GASTROENTEROL, V40, P337
[8]  
KANAI T, 1987, CANCER, V60, P810, DOI 10.1002/1097-0142(19870815)60:4<810::AID-CNCR2820600417>3.0.CO
[9]  
2-1
[10]   Significant influence of accompanying chronic hepatitis status on recurrence of hepatocellular carcinoma after hepatectomy - Result of multivariate analysis [J].
Ko, S ;
Nakajima, Y ;
Kanehiro, H ;
Hisanaga, M ;
Aomatsu, Y ;
Kin, T ;
Yagura, K ;
Ohyama, T ;
Nishio, K ;
Ohashi, K ;
Sho, M ;
Yamada, T ;
Nakano, H .
ANNALS OF SURGERY, 1996, 224 (05) :591-595